BSX · Healthcare
BOSTON SCIENTIFIC CORP
Ranked earnings events from SEC filings, earnings calls, press releases and news. Full Picture: what to focus on this earnings window
News · 2026-09-23
- Leadership TransitionImportance 25 · Surprise 42Arthur C. Butcher will retire as Boston Scientific’s Executive Vice President and Group President of MedSurg and Asia Pacific effective January 1, 2027. He will remain with the company as a senior advisor through…
News · 2026-09-17
- Product Safety RecallImportance 47 · Surprise 60Boston Scientific initiated a voluntary global recall of the LUX-Dx Insertable Cardiac Monitor System and associated software. The recall concerns delays in atrial fibrillation Burden Alerts, which could affect timely…
- Cybersecurity Incident DisruptionImportance 40 · Surprise 42Citi identified a cybersecurity attack as one of Boston Scientific’s 2026 setbacks. The analyst said the effects could remain protracted, creating continued disruption beyond the initial incident. The cybersecurity…
- Competition and Market ShareImportance 20 · Surprise 24Boston Scientific faces near-term pressure in electrophysiology as Medtronic reportedly gains share and shows stronger momentum across key franchises. Citi also cited increased competition in pulsed field ablation,…
News · 2026-09-14
- Acquisition / Partnership / DivestitureImportance 24 · Surprise 24Boston Scientific is using acquisitions to expand into high-growth markets, according to the report. Penumbra is identified as adding a major thrombectomy opportunity to Boston Scientific’s growth strategy. The digest…
News · 2026-09-13
- Cybersecurity Incident DisruptionImportance 47 · Surprise 60Boston Scientific experienced a cyberattack on August 25, 2026, that disrupted manufacturing and shipping operations. The company expects to miss its third-quarter 2026 net-sales and adjusted-EPS guidance because of…
- Guidance / OutlookImportance 47 · Surprise 60A cyberattack on August 25, 2026 disrupted Boston Scientific’s manufacturing and shipping operations. Although operations have resumed, the company expects to miss its third-quarter and full-year 2026 guidance for net…
News · 2026-09-11
- Guidance / OutlookImportance 51 · Surprise 60Boston Scientific has withdrawn its earnings forecast for 2026, according to third-party reporting. The report states that a cyberattack is expected to hurt third-quarter 2026 results, although recovered manufacturing…
- Cybersecurity Incident DisruptionImportance 28 · Surprise 42A cyberattack is expected to hurt Boston Scientific’s third-quarter results. Manufacturing and shipping recovered quickly, suggesting that much of the affected revenue may be delayed rather than permanently lost. The…
- WATCHMAN Sales SlowdownImportance 20 · Surprise 24WATCHMAN demand had slowed before the cyberattack, creating an additional risk to Boston Scientific’s revenue performance. U.S. electrophysiology activity also slowed before the cyberattack, indicating weakness beyond…
News · 2026-09-10
- Cybersecurity Incident DisruptionImportance 34 · Surprise 42Boston Scientific restored key operations after a cyberattack reported on September 10, 2026. The company said products were moving through its distribution network at or above normal levels while it worked to fulfill…
News · 2026-09-08
- Cybersecurity Incident DisruptionImportance 57 · Surprise 60A cyberattack that began on August 25, 2026 disrupted Boston Scientific’s global operations, including manufacturing, order processing, distribution, and shipments. The company said it is unlikely to meet its…
News · 2026-09-05
- Cybersecurity Incident DisruptionImportance 57 · Surprise 60A cyberattack that began on August 25, 2026 disrupted Boston Scientific’s global operations, including manufacturing, order processing, distribution, and shipments. The company said it is unlikely to meet its…
- Watchman Sales SlowdownImportance 17 · Surprise 24Third-party reporting cited weaker demand for Boston Scientific’s Watchman heart implant as an additional near-term business pressure. The commentary indicates that Watchman demand weakness is occurring alongside…
News · 2026-09-04
- Cybersecurity Incident DisruptionImportance 57 · Surprise 60A cyberattack that began on August 25, 2026 disrupted Boston Scientific’s global operations, including manufacturing, order processing, distribution, and shipments. The company said it is unlikely to meet its…
- Product Safety RecallImportance 47 · Surprise 60Boston Scientific issued a Class I FDA recall for unused Infinion CX Leads used in its Spinal Cord Stimulator System. The recall addresses a fracture risk that can cause high impedance or loss of stimulation. The…
News · 2026-09-03
- Cybersecurity Incident DisruptionImportance 57 · Surprise 60A cyberattack that began on August 25, 2026 disrupted Boston Scientific’s global operations, including manufacturing, order processing, distribution, and shipments. The company said it is unlikely to meet its…
News · 2026-09-01
- Cybersecurity Incident DisruptionImportance 44 · Surprise 60Boston Scientific disclosed a cyberattack that affected remote-monitoring capabilities for pacemakers. The company is working to restore the affected systems. Boston Scientific is also investigating the incident, but…
News · 2026-08-26
- Supply Chain Cybersecurity RiskImportance 41 · Surprise 60Boston Scientific identified a cybersecurity incident on August 25, 2026, that disrupted global information systems and business applications. The outage affected customer order processing and the ability to ship…
- Cybersecurity Incident DisruptionImportance 41 · Surprise 60Boston Scientific detected a cybersecurity incident on August 25, 2026, that disrupted global information systems and business applications. The disruption affected customer order processing and product shipping,…
News · 2026-08-25
- Guidance / OutlookImportance 47 · Surprise 60Boston Scientific has made recent guidance cuts, according to TD Cowen's commentary. The revisions led analysts to reduce their revenue-growth estimates for 2027. Boston Scientific nevertheless exceeded second-quarter…
- Revenue Performance and MixImportance 36 · Surprise 40Boston Scientific reported double-digit year-over-year revenue growth in the period discussed. The company surpassed second-quarter revenue expectations, according to third-party reporting. The revenue performance was…
News · 2026-08-24
- Guidance / OutlookImportance 53 · Surprise 68Boston Scientific updated its 2026 organic sales-growth guidance to 6.5%-8.0%, below its previous double-digit growth forecast. The revised outlook indicates a moderation in expected revenue growth for 2026. The…
News · 2026-08-20
- Market Demand TrendsImportance 40 · Surprise 56The global cardiovascular devices market is projected to grow from $72.4 billion in 2025 to $101.6 billion by 2030, representing approximately 40% expansion. Growth is expected to be driven by an aging population,…
News · 2026-08-19
- Stock Repurchase ProgramImportance 64 · Surprise 42Boston Scientific has authorized a $5 billion share repurchase program. The authorization was cited alongside reported EPS of $0.86, which exceeded analyst estimates. The news report did not provide a repurchase…
- Market Demand TrendsImportance 40 · Surprise 56The global cardiovascular devices market is projected to grow from $72.4 billion in 2025 to $101.6 billion by 2030, representing approximately 40% expansion. Growth is expected to be driven by an aging population,…
News · 2026-08-18
- Stock Repurchase ProgramImportance 64 · Surprise 42Boston Scientific authorized a $5 billion share buyback plan. The authorization was cited alongside the company’s recently reported strong quarterly earnings. The repurchase program indicates management’s stated…
News · 2026-08-17
- Stock Repurchase ProgramImportance 64 · Surprise 42Boston Scientific announced a $5.00 billion share buyback program, according to the August 17, 2026 third-party report. The repurchase authorization represents a material capital-allocation commitment relative to the…
- Watchman Demand SlowdownImportance 20 · Surprise 24Aristotle Capital Management’s Core Equity Fund sold its Boston Scientific position because of concerns about slowing growth in the company’s Watchman and Farapulse medical-device franchises. Watchman growth is…
News · 2026-08-14
- Stock Repurchase ProgramImportance 64 · Surprise 42Boston Scientific announced a $5 billion share-repurchase program. The announcement was reported alongside quarterly adjusted EPS of $0.86 and revenue of $5.44 billion, although those performance metrics are outside…
- Revenue Performance and MixImportance 36 · Surprise 6Boston Scientific reported quarterly revenue of $5.44 billion, exceeding analyst expectations. Adjusted EPS was $0.86 for the quarter. The company’s EP and WATCHMAN businesses experienced slowdowns, while 74% of its…
- Product Pipeline ProgressImportance 28 · Surprise 42Boston Scientific is expected to use new EP products, including FARAWAVE Ultra and ICE, to address weakness in its electrophysiology business. The products are cited as potential drivers of an EP recovery beginning in…
- Watchman Demand SlowdownImportance 20 · Surprise 24Third-party reporting identifies slowdowns in Boston Scientific’s electrophysiology (EP) and WATCHMAN businesses as key headwinds. The report states that 74% of the company’s portfolio continues to show healthy growth,…
News · 2026-08-13
- Stock Repurchase ProgramImportance 58 · Surprise 42Boston Scientific authorized a $5 billion share-repurchase program, according to third-party reporting. The authorization was cited alongside institutional ownership activity and recent quarterly results. The digest…
- Revenue Performance and MixImportance 24 · Surprise 14Boston Scientific reported second-quarter revenue of $5.44 billion, up 7.5% year over year. Second-quarter EPS was $0.86, and the company exceeded analyst expectations for both revenue and earnings. The reported…
News · 2026-08-12
- Stock Repurchase ProgramImportance 64 · Surprise 42Boston Scientific has authorized a $5 billion share repurchase program. Third-party reports cited the authorization alongside the company’s recent quarterly results and institutional ownership data. The reported…
- Acquisition / Partnership / DivestitureImportance 58 · Surprise 42Boston Scientific is investing $1.5 billion in Marietta, Georgia-based MiRus to support its heart-valve replacement technology. MiRus is pursuing U.S. Food and Drug Administration approval for a heart valve using a…
- Revenue Performance and MixImportance 6 · Surprise 6Boston Scientific reported quarterly revenue of approximately $5.44 billion. Adjusted quarterly EPS was $0.86, and the results exceeded analyst expectations. The digest does not provide segment revenue, geographic…
News · 2026-08-11
- Capital Return ProgramImportance 64 · Surprise 42Boston Scientific authorized a $5 billion share-repurchase program following its second-quarter 2026 results. The authorization was cited alongside quarterly revenue of $5.44 billion and adjusted EPS of $0.86. The…
- Guidance / OutlookImportance 45 · Surprise 60Third-party reporting says Boston Scientific has issued multiple guidance cuts in 2026. The company faces U.S. growth headwinds in WATCHMAN and electrophysiology. International markets are described as providing…
- Revenue Performance and MixImportance 36 · Surprise 14Boston Scientific reported second-quarter 2026 revenue of $5.44 billion, representing 7.5% year-over-year growth. International electrophysiology sales increased 23.1%, while international WATCHMAN sales increased…
- Geographic Market CommentaryImportance 35 · Surprise 48Boston Scientific is experiencing headwinds in the United States for its WATCHMAN and electrophysiology businesses. International markets are showing stronger demand, with electrophysiology sales up 23.1% and WATCHMAN…
News · 2026-08-10
- Capital Return ProgramImportance 64 · Surprise 42Boston Scientific authorized a $5 billion share-repurchase program following its second-quarter 2026 results. The authorization was cited alongside quarterly revenue of $5.44 billion and adjusted EPS of $0.86. The…
- Guidance / OutlookImportance 45 · Surprise 60Third-party reporting says Boston Scientific has issued multiple guidance cuts in 2026. The company faces U.S. growth headwinds in WATCHMAN and electrophysiology. International markets are described as providing…
- Revenue Performance and MixImportance 36 · Surprise 14Boston Scientific reported second-quarter 2026 revenue of $5.44 billion, representing 7.5% year-over-year growth. International electrophysiology sales increased 23.1%, while international WATCHMAN sales increased…
- Litigation and Legal RiskImportance 31 · Surprise 42A third-party legal report states that a multidistrict litigation proceeding has already been established for Boston Scientific spinal cord stimulator cases. The report concerns alleged device defects and contrasts…
News · 2026-08-09
- Capital Return ProgramImportance 64 · Surprise 42Boston Scientific authorized a $5 billion share-repurchase program following its second-quarter 2026 results. The authorization was cited alongside quarterly revenue of $5.44 billion and adjusted EPS of $0.86. The…
- Revenue Performance and MixImportance 36 · Surprise 14Boston Scientific reported second-quarter 2026 revenue of $5.44 billion, representing 7.5% year-over-year growth. International electrophysiology sales increased 23.1%, while international WATCHMAN sales increased…
News · 2026-08-07
- Guidance / OutlookImportance 47 · Surprise 60Third-party reporting says Boston Scientific cut its 2026 guidance after weakness in the WATCHMAN business, electrophysiology share losses, and delayed margin improvement. The reports characterize the reduction as…
- Product Safety RecallImportance 47 · Surprise 60Boston Scientific has initiated multiple U.S. Class II recalls involving cardiac ablation generators and vascular access sheaths. Reported issues include labeling discrepancies and risks of air embolism, affecting…
News · 2026-08-06
- Guidance / OutlookImportance 47 · Surprise 60Third-party reporting says Boston Scientific cut its 2026 guidance after weakness in the WATCHMAN business, electrophysiology share losses, and delayed margin improvement. The reports characterize the reduction as…
- Competition and Market ShareImportance 26 · Surprise 24Third-party analysis cited share losses for Boston Scientific in electrophysiology (EP), indicating competitive pressure in cardiac rhythm procedures. The commentary also identified weakness in the WATCHMAN device…
News · 2026-08-05
- Revenue Performance and MixImportance 42 · Surprise 32Boston Scientific reported June-quarter revenue of $5.44 billion on July 29, 2026. Revenue increased 7.5% year over year, exceeding the $163 million materiality threshold. The reported growth reflects performance…
- Competition and Market ShareImportance 26 · Surprise 24Third-party analysis cited share losses for Boston Scientific in electrophysiology (EP), indicating competitive pressure in cardiac rhythm procedures. The commentary also identified weakness in the WATCHMAN device…
News · 2026-08-04
- Competition and Market ShareImportance 26 · Surprise 24Third-party analysis cited share losses for Boston Scientific in electrophysiology (EP), indicating competitive pressure in cardiac rhythm procedures. The commentary also identified weakness in the WATCHMAN device…
10-Q · 2026-08-03
- Trade Policy and TariffsImportance 37 · Surprise 42Boston Scientific cites significant uncertainty in global trade policies, including changing tariff rates, delayed tariff impositions and potential reciprocal restrictions by the U.S. or other governments. The company…
- Geographic Market CommentaryImportance 31 · Surprise 32China was a specific area of weakness in Boston Scientific’s Urology business during the second quarter and first six months of 2026. The company attributed underperformance in its stone franchise to volume-based…
- Liquidity and Capital PositionImportance 31 · Surprise 6Boston Scientific expects cash, operating cash generation, capital-market access and credit facilities to fund operations, infrastructure investment, legal liabilities, taxes, debt service, repayment and possible…
- Products and TechnologyImportance 23 · Surprise 24Endoscopy growth was led by the biliary franchise, particularly the AXIOS™ Stent and Delivery System, along with the core GI franchise. Neuromodulation demand was driven by the Intracept™ Intraosseous Nerve Ablation…
- Competition and Market ShareImportance 23 · Surprise 24Boston Scientific said increased competition in its Electrophysiology business unit affected Cardiovascular sales in both the second quarter and first six months of 2026. The company also reported a deceleration in…